As President Donald Trump vows to bridge the drug pricing gap between the U.S. and other developed countries with his “most ...

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

The decision of the General Court of the European Union in the Pfizergate case would allow the European Commission to ...

CEO Albert Bourla has reportedly said that the company has made no commitments during its meeting with the Trump ...

Pfizer Inc. (NYSE:PFE) is one of the best wide moat stocks to buy now. On June 9, Pfizer, along with other drug manufacturers ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services terminated a contract with drugmaker Moderna to develop an mRNA bird flu ...

Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.

Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no ...

When a novel coronavirus struck in early 2020, Pfizer’sPFE1.47%increase; green up pointing triangle chief executive, Dr. Albert Bourla, saw an opportunity to help save the world. He pushed the ...

In today’s CEO Daily: Diane Brady talks to Pfizer CEO Albert Bourla about defending science amid a backdrop of political threats. The big story: Trump’s tariff regime is open to compromises.

You can reach Adam on Signal at stataf.54. It’s only February, but my pick for the Worst Biopharma CEO of 2025 has already been decided: Albert Bourla of Pfizer. Pfizer’s decision to hire ...